Press Releases | Arnold Ventures

Sens. Cassidy and Hassan Release Bipartisan Site-Neutral Payment Reform Framework

11.01.2024

Arnold Ventures Optimistic Upon Seeing the First Round of Medicare Negotiated Drug Prices Announced

08.15.2024

Arnold Ventures Commends Senate on Unanimous Passage of the Affordable Prescriptions for Patients Act

07.11.2024

Jennifer Laudano Joins Arnold Ventures as Vice President of Advocacy, Health Care

06.03.2024

Meaningful Reforms Need to be Enacted Sooner Rather Than Later to Protect Medicare Program

05.07.2024

Arnold Ventures Applauds CMS’ Efforts to Rein in Medicare Advantage Costs, Notes 2025 Medicare Rates Include $16 Billion Increase in Plan Payments

04.03.2024

12 Million Vulnerable Seniors Could See Improved Access to Health Care with New Bipartisan Legislation

03.14.2024

Statement from Arnold Ventures Executive Vice President of Health Care, Mark E. Miller on the Release of the No Surprises Act IDR Reports

02.16.2024

Statement from Arnold Ventures Executive Vice President of Health Care, Mark E. Miller on the Additional $16 Billion in Plan Payments in Proposed Medicare Advantage and Part‑D Rate Notice

02.01.2024

Statement From Arnold Venture’s Mark E. Miller on the U.S. House of Representatives Passage of the Lower Costs, More Transparency Act, a Critical Step Forward in Addressing Rising Health Care Costs

12.12.2023

Health Policy Leaders Launch Coalition to Protect Consumers and Employers from Predatory Health Care Pricing

09.13.2023

New Law Goes Into Effect to Strengthen The Maryland Prescription Drug Affordability Board

04.11.2023

Statement from Arnold Ventures’ Mark E. Miller on Biden Administration’s Decision to Slow Implementation of Medicare Advantage Reforms

03.31.2023

California Selects Civica Rx as Its Insulin Manufacturing Partner

03.20.2023

New Survey Shows Americans Overwhelmingly Believe Congress and the Biden Administration Should Crack Down on Medicare Advantage Insurers for Abusive Billing Practices

03.20.2023

Statement on the Biden Administration’s Final Regulations to Implement the No Surprises Act

08.19.2022

Statement from Laura and John Arnold on Landmark Law to Lower Prescription Drug Prices

08.16.2022

Statement from Laura and John Arnold Following Senate Passage of the Inflation Reduction Act of 2022

08.07.2022

“It’s time to finish the job.”: Statement from Mark E. Miller on Historic Opportunity for Congress to Lower Prescription Drug Prices

06.30.2022

Statement from Mark E. Miller on Medicare Advantage Oversight Hearing

06.27.2022

Statement from Mark E. Miller on New Insulin Legislation Offered in Senate

06.23.2022

Statement from Arnold Ventures’ Mark Miller on Federal Judge’s Ruling on Surprise Billing Arbitration Process

02.24.2022

Arnold Ventures’ Statement on the Removal of Drug Pricing from the Build Back Better Framework

10.28.2021

No Surprises Act Implementation Positive Sign for Patients Hurt By Surprise Bills

10.01.2021